Iguana Healthcare Management LLC lessened its stake in shares of Eli Lilly and Co (NYSE:LLY) by 20.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 40,000 shares of the company’s stock after selling 10,000 shares during the period. Eli Lilly and accounts for approximately 1.8% of Iguana Healthcare Management LLC’s investment portfolio, making the stock its 20th biggest position. Iguana Healthcare Management LLC’s holdings in Eli Lilly and were worth $3,422,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. Acrospire Investment Management LLC raised its position in shares of Eli Lilly and by 16.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC purchased a new stake in Eli Lilly and during the 2nd quarter valued at about $128,000. San Francisco Sentry Investment Group CA purchased a new stake in Eli Lilly and during the 2nd quarter valued at about $129,000. Willingdon Wealth Management purchased a new stake in Eli Lilly and during the 3rd quarter valued at about $138,000. Finally, Wealthcare Advisory Partners LLC purchased a new stake in Eli Lilly and during the 3rd quarter valued at about $142,000. Hedge funds and other institutional investors own 76.30% of the company’s stock.
In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Susan Mahony sold 36,585 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the completion of the sale, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. In the last three months, insiders sold 251,088 shares of company stock valued at $22,041,236. Corporate insiders own 0.20% of the company’s stock.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same quarter in the prior year, the company posted $0.88 EPS. The business’s revenue for the quarter was up 9.0% on a year-over-year basis. sell-side analysts forecast that Eli Lilly and Co will post 4.22 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be paid a $0.5625 dividend. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $2.25 annualized dividend and a dividend yield of 2.60%. Eli Lilly and’s dividend payout ratio is 99.05%.
LLY has been the subject of several research reports. Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 price objective (up previously from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Cowen reaffirmed a “buy” rating and set a $95.00 price objective on shares of Eli Lilly and in a research note on Wednesday, October 4th. Jefferies Group reaffirmed a “buy” rating and set a $89.00 price objective on shares of Eli Lilly and in a research note on Monday, September 11th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $105.00 price objective on shares of Eli Lilly and in a research note on Friday, October 13th. Finally, Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price objective for the company in a research note on Thursday, October 26th. Three analysts have rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the stock. Eli Lilly and has an average rating of “Hold” and an average price target of $92.14.
TRADEMARK VIOLATION NOTICE: “Eli Lilly and Co (LLY) Shares Sold by Iguana Healthcare Management LLC” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.chaffeybreeze.com/2018/01/06/eli-lilly-and-co-lly-shares-sold-by-iguana-healthcare-management-llc.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.